A Comparative Study of Bcl-2 Expression in Oral Leukoplakia with Dysplasia, Verrucous Carcinoma, and Oral Squamous Cell Carcinoma Authors: Bireswar Roy, Shivani Saxena, Narayan Tripathi, Mridul Sharma, Deepmala Rana, N Pramukh, Miral Mehta Published: 2024 ABSTRACT ABSTRACTAim:To study the immunohistochemical expression of Bcl-2 in oral leukoplakia with dysplasia, verrucous carcinoma and oral squamous cell carcinoma(OSCC).Methodology:A total of 80 formalin-fixed , paraffin- embedded specimens were selected , amongst them 30 cases of different grades of dysplasia- 10 mild, 10 moderate and 10 severe and 30 oral squamous cell carcinoma of various grades- 10 well differentiated, 10 moderately differentiated and 10 poorly differentiated, 10 verrucous carcinoma had been included in the study. 10 normal buccal mucosa were used as control group.Results:The immunohistochemical expression of Bcl-2 in oral leukoplakia with different grades of dysplasia, in verrucous carcinoma and in different grades of oral squamous cell carcinoma with normal mucosa were compared. Moreover, the expression of Bcl-2 was found to increase significantly between dysplasia and different grades of oral squamous cell carcinoma.Conclusion:The expression of Bcl-2 has always guided the researchers towards mapping the progression of dysplasia as well as malignant transformation at the molecular level. INTRODUCTION Slaughter proposed the term “Field Cancerization,” which implies that the whole epithelium surface that is repeatedly exposed to carcinogenic insults is at risk, and this exposure raises the possibility of developing many independent pre-malignant lesions and malignant tumors.[1] Most epithelial tissues have pre-malignant lesions found in them. It has been said that dysplasia is the morphological benchmark for lesions originating from epithelial precursors. It is the aggregate term used to describe a range of cytological and architectural alterations within the modified oral epithelium. Vascular endothelial cells mediate this multi-step process, which includes the vasculature’s reaction to many protein mediators.[2] The gene encoding B-cell lymphoma/leukemia-2 (BCL-2) was first identified in non-Hodgkins lymphoma. Pro-apoptotic proteins with anti-apoptotic sections are included. The Bcl-2 oncogene, which encodes a membrane-associated protein found in the nuclear, outer, and endoplasmic reticulum membranes of mitochondria, was initially shown to be the locus of reciprocal translocation of chromosome 18 in follicular lymphoma. Increased Bcl-2 expression in human neoplasms, including lung carcinoma, prostatic carcinoma, breast carcinoma, and lymphoma, points to the involvement of oncoprotein in the pathophysiology of neoplasia.[3] It is yet unknown how important Bcl-2 expression is biologically to the onset and spread of oral cancer. Our research sought to determine potential relationships between Bcl-2 expression and a few clinicopathological characteristics of oral cancer.[4] Bias in the histological report may occur when evaluating oral squamous cell carcinoma, particularly when we are grading well, moderate, and poorly differentiated and verrucous carcinoma as a distinct entity and with various degrees of dysplasia. This may change the treatment approach.[5] Therefore, to eliminate these diagnostic mistakes, this immunohistochemistry investigation is being carried out on various grades of dysplasia, oral squamous cell carcinoma (OSCC), and oral verrucous carcinoma. METHODOLOGY Source of data Seventy (70) formalin-fixed and paraffin-embedded specimens were selected from the oral and maxillofacial pathology department archives at the Bangalore Institute of Dental Sciences and Hospital in Bangalore. The research comprised 30 instances of OSCC of various degrees (10 well differentiated, 10 moderately differentiated, 10 poorly differentiated, and 10 cases of verrucous carcinoma) and 30 cases of dysplasia of different grades (10 mild, 10 moderate, and 10 severe). Ten slices of normal oral mucosa served as the control group. Oral leukoplakia with dysplasia, oral verrucous carcinoma, and incisional, and excisional biopsies of OSCC formed the inclusion criteria, while subjects with other oral mucosal lesions, previously irradiated and recurrent cases, and squamous cell carcinoma of the lip and oropharynx had been excluded from the study. The tissue will be regularly treated in 10% formalin, fixed, and embedded in paraffin. Three 4 μm-thick slices were cut, and one of them will be immunohistochemically stained with a primary Bcl-2 antibody (a rabbit monoclonal antibody). As a secondary antibody, a supersensitive one-step polymer HRP method was used. Using the WHO histological grading system, two oral pathologists assessed the hematoxylin and eosin-stained slides for various degrees of oral epithelial dysplasia, oral verrucous carcinoma, and OSCC. Afterward, the immunohistochemical marker Bcl-2 will be used to stain normal oral mucosal sections, 10 cases of verrucous carcinoma, 30 cases of OSCC of varying degrees (well, moderate, and poorly differentiated), and 30 dysplastic lesions of various grades (mild, moderate, and severe). By counting the positive cells—50 in each field—the number of Bcl-2 positive cells was recorded in 10 distinct high-power fields. To avoid bias, five excellent cells with appropriate cell outlines were selected from each division of the field’s 50 cells, which were counted using a grid pattern that split the field into 10 equal divisions. These regions were tallied twice, and the mean for each portion was determined by taking the arithmetical mean of each area. RESULTS Expression of Bcl-2 in normal mucosa No significant expression was found in normal buccal mucosa. Bcl-2 expression in mild dysplasia in leukoplakic epithelium Bcl-2 expression was found in the cytoplasm of basal and parabasal cell layers of mild dysplastic epithelium, although predominantly it was observed in the basal layer of mild epithelium. Bcl-2 expression in moderate dysplasia of leukoplakic epithelium Bcl-2 expression was predominantly found in the cytoplasm of both basal and parabasal cell layer of moderate dysplasia of leukoplakic epithelium. Although in some cases, greater suprabasal layer-positive staining of Bcl-2 was found. Bcl-2 expression in severe dysplasia of leukoplakic epithelium Bcl-2 expression was found in the cytoplasm of basal, parabasal, and greater suprabasal layers. Bcl-2 expression was observed extending more than middle third of the epithelium in severe dysplasia of leukoplakic epithelium. In severe epithelial dysplasia, the expression of Bcl-2 oncoprotein was found to be more expressive compared to the other grades of dysplasia. A comparison of Bcl-2 expression value in different grades of oral epithelial dysplasia, verrucous carcinoma, and different grades of OSCC is shown in Table 1 Table 1Comparison of Bcl-2 expression value in different grades of oral epithelial dysplasia, verrucous carcinoma and different grades of oral squamous cell carcinomaGroupMinimumMaximumMeanStd DeviationMild dysplasiaBcl -23.129.005.641.85Moderate dysplasiaBcl -24.6215.109.503.609Severe dysplasiaBcl -24.5017.009.794.13VerrucousBcl -26.9021.011.824.09Well DifferentiatedBcl -27.0035.7022.648.51Moderately DifferentiatedBcl -225.6760.0034.1210.13Poorly DifferentiatedBcl -240.60271.2050.0411.26 Comparison of Bcl-2 expression value in different grades of oral epithelial dysplasia, verrucous carcinoma and different grades of oral squamous cell carcinoma DISCUSSION Multiple research avenues have produced evidence linking Bcl-2 family members to the development of cancer. Oral mucosal dysplasia seems to change Bcl-2 expression to varying degrees.[45] Bcl-2 overexpression could be a precursor to epithelial cancer. Bcl-2 is either not present in the normal oral mucosa or is expressed in the basal cells sporadically. When dysplastic epithelium and oral malignancies are present, there is often increased expression of BCL-2. Additionally, we observed elevated Bcl-2 expression in the cytoplasm of the dysplastic epithelium basal cell next to the tumor epithelium, which is consistent with the results reported by Juneja et al.[6] Our study showed that poorly differentiated OSCC had higher Bcl-2 oncoprotein expression. As a result, it has been discovered that Bcl-2 expression has grown along with the malignant transformation and the number of dysplastic characteristics. It is possible that malignant keratinocytes’ diminished capacity for terminal differentiation is the cause of the elevated Bcl-2 expression seen in poorly differentiated carcinomas. In vitro research has also previously shown that Bcl-2 actively expresses the differentiation of cultured keratinocytes. Sudha VM et al.[7] conducted another research. Her research indicates that there may be variations in Bcl-2 expression in oral mucosal dysplasia. Additionally, there is a possibility that Bcl-2 upregulation occurs early in the initiation of epithelial carcinogenesis. Ultimately, her findings suggest that Bcl-2 expression could serve as a useful indicator of tumor behavior and disease prognosis. In a related investigation by Jessica et al.,[8] unlike the 2014 research, which presented a controversial result on Bcl-2 expression, the current investigation provides stronger evidence for Bcl-2 expression across the various study groups. Therefore, we may assume that the more dysplasia or malignant transformation present in those samples, the better the expression of Bcl-2 is boosted. This conclusion is based on the observations, hypothesis, and statistical assessment findings mentioned previously. CONCLUSION Therefore, the BCL-2 gene product may serve as a powerful marker in this respect and may be involved in controlling the cellular and molecular biology of potentially malignant illnesses as well as carcinomas (Dysplasias, Verrucous, and OSCC). Conflicts of interest Nil.